Janki M Desai1, Aniruddha S Karve1, Gary A Gudelsky1, Mruniya V Gawali2, William Seibel3, Larry Sallans4, Biplab DasGupta3, Pankaj B Desai5. 1. Division of Pharmaceutical Sciences, James L. Winkle College of Pharmacy, University of Cincinnati, Cincinnati, OH, USA. 2. Center for Immunotherapy and Precision Immuno-Oncology (CITI), Lerner Research Institute - Cleveland Clinic, Cleveland, OH, USA. 3. Division of Oncology, Cincinnati Children's Hospital, Cincinnati, OH, USA. 4. R. Marshall Wilson Mass Spectrometry Facility, Rieveschl Laboratories for Mass Spectrometry, Department of Chemistry, College of Arts and Sciences, University of Cincinnati, Cincinnati, OH, USA. 5. Division of Pharmaceutical Sciences, James L. Winkle College of Pharmacy, University of Cincinnati, Cincinnati, OH, USA. Pankaj.Desai@uc.edu.
Abstract
PURPOSE: Emerging evidence suggests that 5' Adenosine Monophosphate-Activated Protein Kinase (AMPK), a key regulator of cellular bioenergetics, is a novel target for the treatment of glioblastoma (GBM), a lethal brain tumor. SBI-0206965, an aminopyrimidine derivative, is a potent AMPK inhibitor being investigated for the treatment of GBM. Here we characterized the systemic and brain pharmacokinetics (PK) and hepatic metabolism of SBI-0206965. METHODS: We performed intracerebral microdialysis to determine brain partitioning of SBI-0206965 in jugular vein cannulated rats. We assessed systemic PK of SBI-0206965 in rats and C57BL/6 mice following oral administration. Employing human, mouse, and rat liver microsomes we characterized the metabolism of SBI-0206965. RESULTS: SBI-0206965 is quickly absorbed, achieving plasma and brain extracellular fluid (ECF) peak levels within 0.25 - 0.65 h. Based on the ratio of Cmax and AUC in brain ECF to plasma (corrected for protein binding), brain partitioning is ~ 0.6-0.9 in rats. However, the compound has a short elimination half-life (1-2 h) and low relative oral bioavailability (~ 0.15). The estimated in-vitro hepatic intrinsic clearance of SBI-0206965 in mouse, rat and human was 325, 76 and 68 mL/min/kg, respectively. SBI-0206965 metabolites included desmethylated products, and the metabolism was strongly inhibited by ketoconazole, a CYP3A inhibitor. CONCLUSION: SBI-0206965 has adequate brain permeability but low relative oral bioavailability which may be due to rapid hepatic metabolism, likely catalyzed by CYP3A enzymes. Our observations will facilitate further development of SBI-0206965, and/or other structurally related molecules, for the treatment of GBM and other brain tumors.
PURPOSE: Emerging evidence suggests that 5' Adenosine Monophosphate-Activated Protein Kinase (AMPK), a key regulator of cellular bioenergetics, is a novel target for the treatment of glioblastoma (GBM), a lethal brain tumor. SBI-0206965, an aminopyrimidine derivative, is a potent AMPK inhibitor being investigated for the treatment of GBM. Here we characterized the systemic and brain pharmacokinetics (PK) and hepatic metabolism of SBI-0206965. METHODS: We performed intracerebral microdialysis to determine brain partitioning of SBI-0206965 in jugular vein cannulated rats. We assessed systemic PK of SBI-0206965 in rats and C57BL/6 mice following oral administration. Employing human, mouse, and rat liver microsomes we characterized the metabolism of SBI-0206965. RESULTS: SBI-0206965 is quickly absorbed, achieving plasma and brain extracellular fluid (ECF) peak levels within 0.25 - 0.65 h. Based on the ratio of Cmax and AUC in brain ECF to plasma (corrected for protein binding), brain partitioning is ~ 0.6-0.9 in rats. However, the compound has a short elimination half-life (1-2 h) and low relative oral bioavailability (~ 0.15). The estimated in-vitro hepatic intrinsic clearance of SBI-0206965 in mouse, rat and human was 325, 76 and 68 mL/min/kg, respectively. SBI-0206965 metabolites included desmethylated products, and the metabolism was strongly inhibited by ketoconazole, a CYP3A inhibitor. CONCLUSION: SBI-0206965 has adequate brain permeability but low relative oral bioavailability which may be due to rapid hepatic metabolism, likely catalyzed by CYP3A enzymes. Our observations will facilitate further development of SBI-0206965, and/or other structurally related molecules, for the treatment of GBM and other brain tumors.
Authors: Daniel F Egan; Matthew G H Chun; Mitchell Vamos; Haixia Zou; Juan Rong; Chad J Miller; Hua Jane Lou; Dhanya Raveendra-Panickar; Chih-Cheng Yang; Douglas J Sheffler; Peter Teriete; John M Asara; Benjamin E Turk; Nicholas D P Cosford; Reuben J Shaw Journal: Mol Cell Date: 2015-06-25 Impact factor: 17.970
Authors: Xiaona Liu; Rishi Raj Chhipa; Shabnam Pooya; Matthew Wortman; Sara Yachyshin; Lionel M L Chow; Ashish Kumar; Xuan Zhou; Ying Sun; Brian Quinn; Christopher McPherson; Ronald E Warnick; Ady Kendler; Shailendra Giri; Jeroen Poels; Koenraad Norga; Benoit Viollet; Gregory A Grabowski; Biplab Dasgupta Journal: Proc Natl Acad Sci U S A Date: 2014-01-13 Impact factor: 11.205
Authors: Toby A Dite; Christopher G Langendorf; Ashfaqul Hoque; Sandra Galic; Richard J Rebello; Ashley J Ovens; Lisa M Lindqvist; Kevin R W Ngoei; Naomi X Y Ling; Luc Furic; Bruce E Kemp; John W Scott; Jonathan S Oakhill Journal: J Biol Chem Date: 2018-04-25 Impact factor: 5.157